Paul Hudson, via Getty Images (Bloomberg)

Sanofi walks back Paul Hud­son’s promise of ear­ly vac­cine ac­cess for the US, French min­is­ters call it 'u­nac­cept­able'

Sanofi CEO Paul Hud­son’s com­ments yes­ter­day that the US will get first ac­cess to the com­pa­ny’s Covid-19 vac­cine, should it be ap­proved, were met with swift back­lash yes­ter­day in France, both from his own com­pa­ny and a mem­ber of the French gov­ern­ment.

First, hours af­ter Hud­son’s in­ter­view ap­peared on Bloomberg.com, Sanofi emailed jour­nal­ists a terse state­ments walk­ing back its CEO’s re­marks– sort of. The com­pa­ny said that while vac­cines from US pro­duc­tion will be main­ly pre­served for Amer­i­cans, pro­duc­tion ca­pac­i­ty else­where will sup­ply Eu­rope and the rest of the globe. The tech­nol­o­gy Sanofi us­es for its Covid-19 vac­cine can­di­date is pri­mar­i­ly man­u­fac­tured in the US, al­though the com­pa­ny said it is ex­pand­ing ca­pac­i­ty in ex­ist­ing fa­cil­i­ties in Eu­rope and else­where.

“We have al­ways been com­mit­ted in these un­prece­dent­ed cir­cum­stances to make our vac­cine ac­ces­si­ble to every­one,” they wrote. “Sanofi ben­e­fits from a di­ver­si­fied foot­print around the world. We have man­u­fac­tur­ing ca­pac­i­ty in the US, Eu­rope and all oth­er main re­gions. The US pro­duc­tion will be main­ly for the US and the rest of the man­u­fac­tur­ing ca­pac­i­ty will cov­er Eu­rope and the rest of the world.”

Then a French of­fi­cial ap­peared on a ra­dio show and called any plan to give Amer­i­cans first ac­cess “un­ac­cept­able.”

”For us, it would be un­ac­cept­able that there be priv­i­leged ac­cess for this or that coun­try on a pre­text that would be a fi­nan­cial pre­text,” ju­nior econ­o­my min­is­ter, Agnes Pan­nier-Runach­er, said on an in­ter­view with Sud Ra­dio.

Hud­son told Bloomberg on Wednes­day that “The U.S. gov­ern­ment has the right to the largest pre-or­der” of the ex­per­i­men­tal vac­cine be­cause a US agency, BAR­DA, has fund­ed its de­vel­op­ment. “It’s in­vest­ed in tak­ing the risk,” Hud­son said.

Hud­son’s com­ments en­tered in­to a sim­mer­ing bat­tle over who will get a vac­cine once it’s ap­proved. That bat­tle has par­tic­u­lar­ly cen­tered on the US and the Trump ad­min­is­tra­tion, which has poured over $1 bil­lion in­to top com­pa­nies de­vel­op­ing vac­cines but has es­chewed in­ter­na­tion­al co­op­er­a­tion — in­clud­ing an $8 bil­lion fund raised ear­li­er this month — in fa­vor of an in­ter­nal and thus far vague­ly de­fined ef­fort to get Amer­i­cans in­oc­u­lat­ed first.

The de­bate be­gan in earnest in March, when Reuters and a lead­ing Ger­man news­pa­per re­port­ed that the Trump ad­min­is­tra­tion tried to lure Ger­man mR­NA vac­cine com­pa­ny Cure­Vac to the Unit­ed States. Al­though Cure­Vac de­nied the re­ports, Ger­man sci­en­tists and of­fi­cials re­spond­ed with dis­may and ac­ri­mo­ny, con­demn­ing ef­forts for any coun­try to se­cure ex­clu­sive ac­cess to a vac­cine. The EU sub­se­quent­ly gave Cure­Vac an $89 mil­lion grant, in part to ex­pand man­u­fac­tur­ing on the con­ti­nent.

Since then, As­traZeneca has al­so promised some ear­ly ac­cess to the UK for the vac­cine its build­ing out of Ox­ford, while some world lead­ers have called for more uni­ver­sal ac­cess. To­day, UN­AIDS and OX­FAM re­leased a let­ter call­ing for a “Peo­ple’s Vac­cine” by which the WHO “es­tab­lish­es a glob­al and eq­ui­table rapid man­u­fac­tur­ing and dis­tri­b­u­tion plan – that is ful­ly-fund­ed by rich na­tions – for the vac­cine and all COVID-19 prod­ucts and tech­nolo­gies that guar­an­tees trans­par­ent ‘at true cost-prices.”

The lead­ing vac­cine man­u­fac­tur­ers are tak­ing ef­forts to dra­mat­i­cal­ly ex­pand ca­pac­i­ty, but ex­perts warn that any vac­cines will come in batch­es, rather than all at once.

BAR­DA, found­ed in 2005 to pro­tect the US from bi­o­log­ic threats, is fund­ing some of the world’s lead­ing Covid-19 vac­cine ef­forts, back­ing not on­ly Sanofi, but al­so putting around $1 bil­lion be­hind J&J and Mod­er­na’s ef­forts. Over the last 15 years, they have fund­ed both Sanofi and its re­com­bi­nant vac­cine sub­sidiary Pro­tein Sci­ences, which is mak­ing the Covid-19 vac­cine, to shore up ca­pac­i­ty to build a pan­dem­ic vac­cine. This spring, they in­vest­ed around $30 mil­lion be­hind the Pro­tein Sci­ences ef­fort.

Pro­tein Sci­ences’ re­com­bi­nant vac­cines are pri­mar­i­ly made at a BAR­DA-fund­ed fa­cil­i­ty in Pearl Riv­er, New York. The com­pa­ny’s BAR­DA-fund­ed man­u­fac­tur­ing fa­cil­i­ty in Swift­wa­ter, Penn­syl­va­nia will al­so be used. There is an ad­di­tion­al part­ner­ship with Uni­gen in Japan.

In his re­marks, Hud­son was crit­i­cal of Eu­rope for fail­ing to back pri­vate vac­cine ef­forts, call­ing the US and Chi­na a “mod­el” of pri­vate-pub­lic part­ner­ship and warn­ing, “don’t let Eu­rope be left be­hind.” The French phar­ma gi­ant said they are work­ing on ex­pe­dit­ing the process of get­ting vac­cines to Eu­rope.

“The co­op­er­a­tion we have with BAR­DA in the US al­lows us to ini­ti­ate pro­duc­tion as ear­ly as pos­si­ble while we con­tin­ue to de­vel­op and reg­is­ter the vac­cine,” Sanofi said. “In the mean­time, we are very en­cour­aged to see the mo­bi­liza­tion of the EU Com­mis­sion over the past weeks, ex­plor­ing sim­i­lar mea­sures that could ex­pe­dite both vac­cines de­vel­op­ment and ac­cess to the Eu­ro­pean pop­u­la­tion. We are hav­ing very con­struc­tive con­ver­sa­tions with the EU in­sti­tu­tions and the French and Ger­man gov­ern­ment amongst oth­ers.”

For a look at all End­points News coro­n­avirus sto­ries, check out our spe­cial news chan­nel.

The DCT-OS: A Tech­nol­o­gy-first Op­er­at­ing Sys­tem - En­abling Clin­i­cal Tri­als

As technology-enabled clinical research becomes the new normal, an integrated decentralized clinical trial operating system can ensure quality, deliver consistency and improve the patient experience.

The increasing availability of COVID-19 vaccines has many of us looking forward to a time when everyday things return to a state of normal. Schools and teachers are returning to classrooms, offices and small businesses are reopening, and there’s a palpable sense of optimism that the often-awkward adjustments we’ve all made personally and professionally in the last year are behind us, never to return. In the world of clinical research, however, some pandemic-necessitated adjustments are proving to be more than emergency stopgap measures to ensure trial continuity — and numerous decentralized clinical trial (DCT) tools and methodologies employed within the last year are likely here to stay as part of biopharma’s new normal.

As­traZeneca caps PD-L1/CT­LA-4/chemo com­bo come­back with OS win. Is treme­li­mum­ab fi­nal­ly ready for ap­proval?

AstraZeneca’s closely-watched POSEIDON study continues to be the rare bright spot in its push for an in-house PD-L1/CTLA-4 combo.

Combining Imfinzi and tremelimumab with physicians’ choice of chemotherapy helped patients with stage IV non-small cell lung cancer live longer, the company reported — marking the first time the still-experimental tremelimumab has demonstrated an OS benefit.

For AstraZeneca and CEO Pascal Soriot, the positive readout — which is devoid of numbers — offers much-needed validation for the big bet they made on Imfinzi plus tremelimumab, after the PD-L1/CTLA-4 regimen failed multiple trials in head and neck cancer as well as lung cancer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Onno van de Stolpe, Galapagos CEO (Thierry Roge/Belga Mag/AFP via Getty Images)

Gala­pa­gos chops in­to their pipeline, drop­ping core fields and re­or­ga­niz­ing R&D as the BD team hunts for some­thing 'trans­for­ma­tive'

Just 5 months after Gilead gutted its rich partnership with Galapagos following a bitter setback at the FDA, the Belgian biotech is hunkering down and chopping the pipeline in an effort to conserve cash while their BD team pursues a mission to find a “transformative” deal for the company.

The filgotinib disaster didn’t warrant a mention as Galapagos laid out its Darwinian restructuring plans. Forced to make choices, the company is ditching its IPF molecule ’1205, while moving ahead with a Phase II IPF study for its chitinase inhibitor ’4617.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Stéphane Bancel, Getty

Mod­er­na CEO brush­es off US sup­port for IP waiv­er, eyes more than $19B in Covid-19 vac­cine sales in 2021

Moderna is definitively more concerned with keeping pace with Pfizer in the race to vaccinate the world against Covid-19 than it is with Wednesday’s decision from the Biden administration to back an intellectual property waiver that aims to increase vaccine supplies worldwide.

In its first quarter earnings call on Thursday, Moderna CEO Stéphane Bancel shrugged off any suggestion that the newly US-backed intellectual property waiver would impact his company’s vaccine or bottom line. Still, the company’s stock price fell by about 9% in early morning trading.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Ron DePinho (file photo)

A 'fly­over' biotech launch­es in Texas with four Ron De­Pin­ho-found­ed com­pa­nies un­der its belt

In his 13 years at Genzyme, Michael Wyzga noticed something about East Coast drugmakers. Execs would often jet from Boston or New York to San Francisco to find more assets, and completely miss the work being done in flyover states, like Texas or Wisconsin.

“If it doesn’t come out of MGH or MIT or Harvard, probably not that interesting,” he said of the mindset.

Now, he and some well-known industry players are looking to change that, and they’ve reeled in just over $38 million to do it.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Ad­comm splits slight­ly in fa­vor of FDA ap­prov­ing Chemo­Cen­tryx’s rare dis­ease drug

The FDA’s Arthritis Advisory Committee on Thursday voted 10 for and 8 against the approval of ChemoCentryx’s $CCXI investigational drug avacopan as a treatment for adults with a rare and serious disease known as anti-neutrophil cytoplasmic autoantibody (ANCA)-vasculitis.

The vote on whether the FDA should approve the drug was preceded by a split vote of 9 to 9 on whether the efficacy data support approval, and 10 to 8 that the safety profile of avacopan is adequate enough to support approval.

Paul Hastings, Nkarta CEO

With no up­front pay­ment or mile­stones on the line, Nkar­ta and CRISPR join forces on CAR-NK search

Most deals in biotech come with hefty upfront payments attached, and the promise of big biobucks if a program works out. Not this one.

Nkarta has struck what CEO Paul Hastings calls a “real collaboration” with CRISPR Therapeutics to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T program. The duo will split all R&D costs — and any worldwide profits — 50/50, Hastings said.

Brent Saunders (Richard Drew, AP Images)

OcuWho? Star deal­mak­er turned aes­thet­ics czar Brent Saun­ders flips back in­to biotech. But who’s he team­ing up with now?

Brent Saunders went on a tear of headline-blazing deals building Allergan, merging and rearranging a variety of big companies into one before an M&A pact with Pfizer blew up and sent him on a bout of biotech drug deals. That didn’t work so well, so under pressure, he got his buyout at AbbVie — which needed a big franchise like Botox. And it was no big surprise to see him riding the SPAC wave into a recent $1 billion-plus deal that left him in the executive chairman’s seat at an aesthetics outfit — now redubbed The Beauty Health Company — holding a big chunk of the equity.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Drug pric­ing watch­dog joins the cho­rus of crit­ics on Bio­gen's ad­u­canum­ab: What about charg­ing $2,560 per year?

As if Biogen’s aducanumab isn’t controversial enough, the researchers at drug pricing watchdog ICER have drawn up the contours of a new debate: If the therapy does get approved for Alzheimer’s by June, what price should it command?

Their answer: At most $8,290 per year — and perhaps as little as $2,560.

Even at the top of the range, the proposed price is a fraction of the $50,000 that Wall Street has reportedly come to expect (although RBC analyst Brian Abrahams puts the consensus figure at $11.5K). With critics, including experts on the FDA’s advisory committee, making their fierce opposition to aducanumab’s approval loud and clear, the pricing pressure adds one extra wrinkle Biogen CEO Michel Vounatsos doesn’t need as he orders full-steam preparation for a launch.